메뉴 건너뛰기




Volumn 9, Issue 11, 2012, Pages 631-642

Targeted therapy in rare cancers-adopting the orphans

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; B RAF KINASE INHIBITOR; BRENTUXIMAB VEDOTIN; CABOZANTINIB; CRIZOTINIB; DACARBAZINE; DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; INSULIN LIKE GROWTH FACTOR 1 RECEPTOR INHIBITOR; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR ANTIBODY; LENALIDOMIDE; MET INHIBITOR; NILOTINIB; PLACEBO; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; RETINOIC ACID; RUXOLITINIB; SILTUXIMAB; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; VANDETANIB; VEMURAFENIB;

EID: 84868204526     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.160     Document Type: Review
Times cited : (32)

References (125)
  • 1
    • 77956401725 scopus 로고    scopus 로고
    • Equipoise lost: Ethics, costs, and the regulation of cancer clinical research
    • Stewart, D. J., Whitney, S. N. & Kurzrock, R. Equipoise lost: Ethics, costs, and the regulation of cancer clinical research. J. Clin. Oncol. 28, 2925-2935 (2010
    • (2010) J. Clin. Oncol , vol.28 , pp. 2925-2935
    • Stewart, D.J.1    Whitney, S.N.2    Kurzrock, R.3
  • 2
    • 57649109461 scopus 로고    scopus 로고
    • Clinical research for rare disease: Opportunities, challenges, and solutions
    • Griggs, R. C. et al. Clinical research for rare disease: Opportunities, challenges, and solutions. Mol. Genet. Metab. 96, 20-26 (2009
    • (2009) Mol. Genet. Metab , vol.96 , pp. 20-26
    • Griggs, R.C.1
  • 3
    • 84868203763 scopus 로고    scopus 로고
    • eds Mehta A. Beck M. & Sunder-Plassmann G.) Ch. 11 Oxford PharmaGenesis, Oxford
    • Shah, R. R. in Fabry Disease: perspectives from 5 Years of FOS (eds Mehta, A., Beck, M. & Sunder-Plassmann, G.) Ch. 11 (Oxford PharmaGenesis, Oxford, 2006
    • (2006) Fabry Disease: perspectives From 5 Years Of FOS
    • Shah, R.R.1
  • 5
    • 56749132011 scopus 로고    scopus 로고
    • Heterogeneity in cancer guidelines: Should we eradicate or tolerate
    • Orphan Drug Act No 97- 414 PubL 1983
    • Pentheroudakis, G. et al. Heterogeneity in cancer guidelines: Should we eradicate or tolerate? Ann. Oncol. 19, 2067-2078 (2008 Orphan Drug Act. No. 97-414 Pub. L (1983
    • (2008) Ann Oncol , vol.19 , pp. 2067-2078
    • Pentheroudakis, G.1
  • 7
    • 80755140638 scopus 로고    scopus 로고
    • Rare cancers are not so rare: The rare cancer burden in Europe
    • Gatta, G. et al. Rare cancers are not so rare: The rare cancer burden in Europe. Eur. J. Cancer 47, 2493-2511 (2011
    • (2011) Eur. J. Cancer , vol.47 , pp. 2493-2511
    • Gatta, G.1
  • 10
    • 55049089102 scopus 로고    scopus 로고
    • Prevalence of zebras in general practice: Data from the Continuous Morbidity Registration Nijmegen
    • Van De Laar F. A., Bor, H. & van de Lisdonk, E. H. Prevalence of zebras in general practice: Data from the Continuous Morbidity Registration Nijmegen. Eur. J. Gen. Pract. 14 (Suppl. 1), 44-46 (2008
    • (2008) Eur J. Gen. Pract , vol.14 , Issue.SUPPL. 1 , pp. 44-46
    • Van De Laar, F.A.1    Bor, H.2    Van De Lisdonk, E.H.3
  • 11
    • 15544389968 scopus 로고    scopus 로고
    • What is targeted therapy
    • Sledge, G. W. Jr. What is targeted therapy? J. Clin. Oncol. 23, 1614-1615 (2005
    • (2005) J. Clin. Oncol , vol.23 , pp. 1614-1615
    • Sledge Jr., G.W.1
  • 12
    • 84863897798 scopus 로고    scopus 로고
    • Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A biomarker evaluation from the AVAGAST randomized phase III trial
    • Van Cutsem, E. et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A biomarker evaluation from the AVAGAST randomized phase III trial. J. Clin. Oncol. 30, 2119-2127 (2012
    • (2012) J. Clin. Oncol , vol.30 , pp. 2119-2127
    • Van Cutsem, E.1
  • 13
    • 84862859820 scopus 로고    scopus 로고
    • Safety, activity, and immune correlates of anti PD 1 antibody in cancer
    • Topalian, S. L. et al. Safety, activity, and immune correlates of anti PD 1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012
    • (2012) N. Engl. J. Med , vol.366 , pp. 2443-2454
    • Topalian, S.L.1
  • 15
    • 34248204234 scopus 로고    scopus 로고
    • Uncommon tumors and exceptional therapies: Paradox or paradigm
    • Braiteh, F. & Kurzrock, R. Uncommon tumors and exceptional therapies: paradox or paradigm? Mol. Cancer Ther. 6, 1175-1179 (2007
    • (2007) Mol. Cancer Ther , vol.6 , pp. 1175-1179
    • Braiteh, F.1    Kurzrock, R.2
  • 16
    • 83455176258 scopus 로고    scopus 로고
    • Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma
    • Snuderl, M. et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20, 810-817 (2011
    • (2011) Cancer Cell , vol.20 , pp. 810-817
    • Snuderl, M.1
  • 17
    • 84863393080 scopus 로고    scopus 로고
    • Intratumor heterogeneity and branched evolution revealed by multiregion sequencing
    • Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012
    • (2012) N. Engl. J. Med , vol.366 , pp. 883-892
    • Gerlinger, M.1
  • 18
    • 84862526929 scopus 로고    scopus 로고
    • The clonal and mutational evolution spectrum of primary triple-negative breast cancers
    • Shah, S. P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395-399 (2012
    • (2012) Nature , vol.486 , pp. 395-399
    • Shah, S.P.1
  • 19
    • 78049426513 scopus 로고    scopus 로고
    • EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors
    • Choi, Y. L. et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363, 1734-1739 (2010
    • (2010) N. Engl. J. Med , vol.363 , pp. 1734-1739
    • Choi, Y.L.1
  • 20
    • 79960127513 scopus 로고    scopus 로고
    • Responses to liposomal doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: Biologic rationale and implications for stem-cell research in breast cancer
    • Moulder, S. et al. Responses to liposomal doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: Biologic rationale and implications for stem-cell research in breast cancer. J. Clin. Oncol. 29, e572-e575 (2011
    • (2011) J. Clin. Oncol , vol.29
    • Moulder, S.1
  • 22
    • 0037103424 scopus 로고    scopus 로고
    • Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
    • Demetri, G. D. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472-480 (2002
    • (2002) N. Engl. J. Med , vol.347 , pp. 472-480
    • Demetri, G.D.1
  • 23
    • 23944489636 scopus 로고    scopus 로고
    • Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup
    • Giagounidis, A. A. et al. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Ann. Hematol. 84, 569-571 (2005
    • (2005) Ann. Hematol , vol.84 , pp. 569-571
    • Giagounidis, A.A.1
  • 24
    • 0027484628 scopus 로고
    • Multi-institutional study of all trans retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia
    • Leukaemia Study Group of the Ministry of Health and Welfare
    • Ohno, R. et al. Leukaemia Study Group of the Ministry of Health and Welfare. Multi-institutional study of all trans retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukemia 7, 1722-1727 (1993
    • (1993) Leukemia , vol.7 , pp. 1722-1727
    • Ohno, R.1
  • 25
    • 84864446464 scopus 로고    scopus 로고
    • How I treat CML blast crisis
    • Hehlmann, R. How I treat CML blast crisis. Blood 120, 737-747 (2012
    • (2012) Blood , vol.120 , pp. 737-747
    • Hehlmann, R.1
  • 26
    • 84861839077 scopus 로고    scopus 로고
    • Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
    • Huang, X., Cortes, J. & Kantarjian, H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118, 3123-3127 (2012
    • (2012) Cancer , vol.118 , pp. 3123-3127
    • Huang, X.1    Cortes, J.2    Kantarjian, H.3
  • 27
    • 0035810142 scopus 로고    scopus 로고
    • Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
    • Druker, B. J. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038-1042 (2001
    • (2001) N. Engl. J. Med , vol.344 , pp. 1038-1042
    • Druker, B.J.1
  • 28
    • 84860571418 scopus 로고    scopus 로고
    • Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure
    • Cornelison, A. M., Kantarjian, H., Cortes, J. & Jabbour, E. Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure. Clin. Lymphoma Myeloma Leuk. 11 (Suppl. 1), S101-S110 (2011
    • (2011) Clin. Lymphoma Myeloma Leuk , vol.11 , Issue.SUPPL. 1
    • Cornelison, A.M.1    Kantarjian, H.2    Cortes, J.3    Jabbour, E.4
  • 29
    • 84861663006 scopus 로고    scopus 로고
    • Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: Detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood
    • Razga, F. et al. Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: Detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood. Mol. Diagn. Ther. 16, 163-166 (2012
    • (2012) Mol. Diagn. Ther , vol.16 , pp. 163-166
    • Razga, F.1
  • 30
    • 84859478963 scopus 로고    scopus 로고
    • Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain
    • Levinson, N. M. & Boxer, S. G. Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain. PLoS ONE 7, e29828 (2012
    • (2012) PLoS ONE , vol.7
    • Levinson, N.M.1    Boxer, S.G.2
  • 31
    • 74549122017 scopus 로고    scopus 로고
    • AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance
    • Azam, M. et al. AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance. Chem. Biol. Drug Des. 75, 223-227 (2010
    • (2010) Chem. Biol. Drug Des , vol.75 , pp. 223-227
    • Azam, M.1
  • 32
    • 84863393301 scopus 로고    scopus 로고
    • Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis
    • Cassier, P. A. et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer 118, 1649-1655 (2012
    • (2012) Cancer , vol.118 , pp. 1649-1655
    • Cassier, P.A.1
  • 33
    • 79955645165 scopus 로고    scopus 로고
    • Dermatofibrosarcoma protuberans-derived fibrosarcoma: Clinical history, biological profile and sensitivity to imatinib
    • Stacchiotti, S. et al. Dermatofibrosarcoma protuberans-derived fibrosarcoma: Clinical history, biological profile and sensitivity to imatinib. Int. J. Cancer 129, 1761-1772 (2011
    • (2011) Int. J. Cancer , vol.129 , pp. 1761-1772
    • Stacchiotti, S.1
  • 34
    • 84863356975 scopus 로고    scopus 로고
    • Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine fullblown leukemia
    • Zhao, L. J. et al. Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine fullblown leukemia. Blood 119, 2873-2882 (2012
    • (2012) Blood , vol.119 , pp. 2873-2882
    • Zhao, L.J.1
  • 35
    • 76949088438 scopus 로고    scopus 로고
    • Deletions of immunoglobulin heavy chain and T cell receptor gene regions are uniquely associated with lymphoid blast transformation of chronic myeloid leukemia
    • Nacheva, E. P. et al. Deletions of immunoglobulin heavy chain and T cell receptor gene regions are uniquely associated with lymphoid blast transformation of chronic myeloid leukemia. BMC Genomics 11, 41 (2010
    • (2010) BMC Genomics , vol.11 , Issue.41
    • Nacheva, E.P.1
  • 36
    • 84861813715 scopus 로고    scopus 로고
    • Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia
    • Beekman, R. et al. Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia. Blood 119, 5071-5077 (2012
    • (2012) Blood , vol.119 , pp. 5071-5077
    • Beekman, R.1
  • 37
    • 42149100512 scopus 로고    scopus 로고
    • Primary extramedullary plasmacytoma: Similarities with and differences from multiple myeloma revealed by interphase cytogenetics
    • Bink, K. et al. Primary extramedullary plasmacytoma: Similarities with and differences from multiple myeloma revealed by interphase cytogenetics. Haematologica 93, 623-626 (2008
    • (2008) Haematologica , vol.93 , pp. 623-626
    • Bink, K.1
  • 38
    • 67649329200 scopus 로고    scopus 로고
    • P53 nuclear accumulation is associated with extramedullary progression of multiple myeloma
    • Sheth, N., Yeung, J. & Chang, H. p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma. Leuk. Res. 33, 1357-1360 (2009
    • (2009) Leuk. Res , vol.33 , pp. 1357-1360
    • Sheth, N.1    Yeung, J.2    Chang, H.3
  • 39
    • 49249114037 scopus 로고    scopus 로고
    • Preceding orbital granulocytic sarcoma in an adult patient with acute myelogenous leukemia with t(8;21): A case study and review of the literature
    • Lee, S. G. et al. Preceding orbital granulocytic sarcoma in an adult patient with acute myelogenous leukemia with t(8;21): A case study and review of the literature. Cancer Genet. Cytogenet. 185, 51-54 (2008
    • (2008) Cancer Genet. Cytogenet , vol.185 , pp. 51-54
    • Lee, S.G.1
  • 40
    • 84863581473 scopus 로고    scopus 로고
    • Myeloma as a model for the process of metastasis: Implications for therapy
    • Ghobrial, I. M. Myeloma as a model for the process of metastasis: Implications for therapy. Blood 120, 20-30 (2012
    • (2012) Blood , vol.120 , pp. 20-30
    • Ghobrial, I.M.1
  • 41
    • 41949111045 scopus 로고    scopus 로고
    • Acute promyelocytic leukemia: From highly fatal to highly curable
    • Wang, Z. Y. & Chen, Z. Acute promyelocytic leukemia: From highly fatal to highly curable. Blood 111, 2505-2515 (2008
    • (2008) Blood , vol.111 , pp. 2505-2515
    • Wang, Z.Y.1    Chen, Z.2
  • 42
    • 80055023000 scopus 로고    scopus 로고
    • Advances in therapies for acute promyelocytic leukemia
    • Kamimura, T., Miyamoto, T., Harada, M. & Akashi, K. Advances in therapies for acute promyelocytic leukemia. Cancer Sci. 102, 1929-1937 (2011
    • (2011) Cancer Sci , vol.102 , pp. 1929-1937
    • Kamimura, T.1    Miyamoto, T.2    Harada, M.3    Akashi, K.4
  • 43
    • 62549083523 scopus 로고    scopus 로고
    • Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia
    • Hu, J. et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc. Natl Acad. Sci. USA 106, 3342-3347 (2009
    • (2009) Proc. Natl Acad. Sci. USA , vol.106 , pp. 3342-3347
    • Hu, J.1
  • 44
    • 34548006143 scopus 로고
    • Localized mediastinal lymph node hyperplasia resembling thymoma
    • Castleman, B., Iverson, L. & Menendez, V. P. Localized mediastinal lymph node hyperplasia resembling thymoma. Cancer 9, 822-830 (1956
    • (1956) Cancer , vol.9 , pp. 822-830
    • Castleman, B.1    Iverson, L.2    Menendez, V.P.3
  • 45
    • 68849122422 scopus 로고    scopus 로고
    • Castleman disease: An update on classification and the spectrum of associated lesions
    • Cronin, D. M. & Warnke, R. A. Castleman disease: An update on classification and the spectrum of associated lesions. Adv. Anat. Pathol. 16, 236-246 (2009
    • (2009) Adv. Anat. Pathol , vol.16 , pp. 236-246
    • Cronin, D.M.1    Warnke, R.A.2
  • 46
    • 0029069445 scopus 로고
    • Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body cavity based lymphomas
    • Cesarman, E., Chang, Y., Moore, P. S. & Knowles, D. M. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body cavity based lymphomas. N. Engl. J. Med. 332, 1186-1191 (1995
    • (1995) N. Engl. J. Med , vol.332 , pp. 1186-1191
    • Cesarman, E.1    Chang, Y.2    Moore, P.S.3    Knowles, D.M.4
  • 47
    • 0031060368 scopus 로고    scopus 로고
    • Human herpesvirus 8 encodes a homolog of interleukin 6
    • Neipel, F. et al. Human herpesvirus 8 encodes a homolog of interleukin 6. J. Virol. 71, 839-842 (1997
    • (1997) J. Virol , Issue.71 , pp. 839-842
    • Neipel, F.1
  • 48
    • 0024540981 scopus 로고
    • Giant lymph node hyperplasia (Castleman's disease) with spontaneous production of high levels of B cell differentiation factor activity
    • Yabuhara, A. et al. Giant lymph node hyperplasia (Castleman's disease) with spontaneous production of high levels of B cell differentiation factor activity. Cancer 63, 260-265 (1989
    • (1989) Cancer , vol.63 , pp. 260-265
    • Yabuhara, A.1
  • 49
    • 0028013066 scopus 로고
    • Brief report: Alleviation of systemic manifestations of Castleman's disease by monoclonal anti interleukin 6 antibody
    • Beck, J. T. et al. Brief report: Alleviation of systemic manifestations of Castleman's disease by monoclonal anti interleukin 6 antibody. N. Engl. J. Med. 330, 602-605 (1994
    • (1994) N. Engl. J. Med , vol.330 , pp. 602-605
    • Beck, J.T.1
  • 50
    • 58149154996 scopus 로고    scopus 로고
    • Mechanisms and pathologic significances in increase in serum interleukin 6 (IL 6) and soluble IL 6 receptor after administration of an anti IL 6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease
    • Nishimoto, N. et al. Mechanisms and pathologic significances in increase in serum interleukin 6 (IL 6) and soluble IL 6 receptor after administration of an anti IL 6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112, 3959-3964 (2008
    • (2008) Blood , vol.112 , pp. 3959-3964
    • Nishimoto, N.1
  • 51
    • 77957283115 scopus 로고    scopus 로고
    • Siltuximab, a novel anti -interleukin 6 monoclonal antibody, for Castleman's disease
    • Van Rhee, F. et al. Siltuximab, a novel anti -interleukin 6 monoclonal antibody, for Castleman's disease. J. Clin. Oncol. 28, 3701-3708 (2010
    • (2010) J. Clin. Oncol , vol.28 , pp. 3701-3708
    • Van Rhee, F.1
  • 52
    • 34748822990 scopus 로고    scopus 로고
    • Cutaneous castleman's disease responds to anti interleukin 6 treatment
    • Ahmed, B. et al. Cutaneous castleman's disease responds to anti interleukin 6 treatment. Mol. Cancer Ther. 6, 2386-2390 (2007
    • (2007) Mol. Cancer Ther , vol.6 , pp. 2386-2390
    • Ahmed, B.1
  • 53
    • 77953441380 scopus 로고    scopus 로고
    • Successful treatment of Castleman's disease with interleukin 1 receptor antagonist (Anakinra
    • El-Osta, H., Janku, F. & Kurzrock, R. Successful treatment of Castleman's disease with interleukin 1 receptor antagonist (Anakinra). Mol. Cancer Ther. 9, 1485-1488 (2010
    • (2010) Mol. Cancer Ther , vol.9 , pp. 1485-1488
    • El-Osta, H.1    Janku, F.2    Kurzrock, R.3
  • 54
    • 79955556128 scopus 로고    scopus 로고
    • Castleman's disease: From basic mechanisms to molecular therapeutics
    • El-Osta, H. E. & Kurzrock, R. Castleman's disease: From basic mechanisms to molecular therapeutics. Oncologist 16, 497-511 (2011
    • (2011) Oncologist , vol.16 , pp. 497-511
    • El-Osta, H.E.1    Kurzrock, R.2
  • 55
    • 79251534679 scopus 로고    scopus 로고
    • Ewing sarcoma: An eponym window to history
    • 2011
    • Cripe, T. P. Ewing sarcoma: An eponym window to history. Sarcoma 2011, 457532 (2011
    • (2011) Sarcoma , pp. 457532
    • Cripe, T.P.1
  • 56
    • 36048961176 scopus 로고    scopus 로고
    • Clinical relevance of molecular genetics to paediatric sarcomas
    • Slater, O. & Shipley, J. Clinical relevance of molecular genetics to paediatric sarcomas. J. Clin. Pathol. 60, 1187-1194 (2007
    • (2007) J. Clin. Pathol , vol.60 , pp. 1187-1194
    • Slater, O.1    Shipley, J.2
  • 58
    • 0029586973 scopus 로고
    • Childhood cancer in Britain: The national registry of childhood tumours and incidence rates 1978-1987
    • Stiller, C. A., Allen, M. B. & Eatock, E. M. Childhood Cancer in Britain: The National Registry of Childhood Tumours and Incidence Rates 1978-1987. Eur. J. Cancer 31A, 2028-2034 (1995
    • (1995) Eur. J. Cancer 31A , pp. 2028-2034
    • Stiller, C.A.1    Allen, M.B.2    Eatock, E.M.3
  • 59
    • 84878883144 scopus 로고    scopus 로고
    • Radiotherapy in metastatic Ewing sarcoma
    • Paulino, A. C., Mai, W. Y. & The, B. S. Radiotherapy in metastatic Ewing sarcoma. Am. J. Clin. Oncol. http://dx.doi.org/10.1097/COC. 0b013e3182467ede.
    • Am. J. Clin. Oncol
    • Paulino, A.C.1    Mai, W.Y.2    The, B.S.3
  • 60
    • 80053994190 scopus 로고    scopus 로고
    • R1507, an anti insulin like growth factor 1 receptor (IGF-1R) antibody, and EWS/FLI 1 si RNA in Ewing's Sarcoma: Convergence at the IGF/IGFR/Akt axis
    • Huang, H. J. et al. R1507, an anti insulin like growth factor 1 receptor (IGF-1R) antibody, and EWS/FLI 1 siRNA in Ewing's sarcoma: Convergence at the IGF/IGFR/Akt axis. PLoS ONE 6, e26060 (2011
    • (2011) PLoS ONE , vol.6
    • Huang, H.J.1
  • 61
    • 77950974697 scopus 로고    scopus 로고
    • A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor I receptor antagonist, in patients with advanced solid tumors
    • Kurzrock, R. et al. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor I receptor antagonist, in patients with advanced solid tumors. Clin. Cancer Res. 16, 2458-2465 (2010
    • (2010) Clin. Cancer Res , vol.16 , pp. 2458-2465
    • Kurzrock, R.1
  • 62
    • 73349099049 scopus 로고    scopus 로고
    • Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1
    • Tolcher, A. W. et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J. Clin. Oncol. 27, 5800-5807 (2009
    • (2009) J. Clin. Oncol , vol.27 , pp. 5800-5807
    • Tolcher, A.W.1
  • 63
    • 80052831572 scopus 로고    scopus 로고
    • Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer
    • Naing, A. et al. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin. Cancer Res. 17, 6052-6060 (2011
    • (2011) Clin. Cancer Res , vol.17 , pp. 6052-6060
    • Naing, A.1
  • 64
    • 79953742425 scopus 로고    scopus 로고
    • Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: Response/resistance signatures
    • Subbiah, V. et al. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: Response/resistance signatures. PLoS ONE 6, e18424 (2011
    • (2011) PLoS ONE , vol.6
    • Subbiah, V.1
  • 65
    • 84855182612 scopus 로고    scopus 로고
    • Diabetes and cancer: Is diabetes causally related to cancer
    • Suh, S. & Kim, K. W. Diabetes and cancer: Is diabetes causally related to cancer? Diabetes Metab. J. 35, 193-198 (2011
    • (2011) Diabetes Metab. J. , vol.35 , pp. 193-198
    • Suh, S.1    Kim, K.W.2
  • 66
    • 84855268036 scopus 로고    scopus 로고
    • Imatinib mesylate: Past successes and future challenges in the treatment of gastrointestinal stromal tumors
    • Ksienski, D. Imatinib mesylate: past successes and future challenges in the treatment of gastrointestinal stromal tumors. Clin. Med. Insights Oncol. 5, 365-379 (2011
    • (2011) Clin. Med. Insights Oncol , vol.5 , pp. 365-379
    • Ksienski, D.1
  • 67
    • 84861759106 scopus 로고    scopus 로고
    • Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: Long-term follow-up results of Radiation Therapy Oncology Group 0132
    • Wang, D. et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: Long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann. Surg. Oncol. 19, 1074-1080 (2012
    • (2012) Ann. Surg. Oncol , vol.19 , pp. 1074-1080
    • Wang, D.1
  • 68
    • 84859187987 scopus 로고    scopus 로고
    • One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial
    • Joensuu, H. et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial. JAMA 307, 1265-1272 (2012
    • (2012) JAMA , vol.307 , pp. 1265-1272
    • Joensuu, H.1
  • 69
    • 84858179982 scopus 로고    scopus 로고
    • KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors (GIST
    • Miranda, C. et al. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors (GIST). Clin. Cancer Res. 18, 1769-1776 (2012
    • (2012) Clin. Cancer Res , vol.18 , pp. 1769-1776
    • Miranda, C.1
  • 70
    • 73949094832 scopus 로고    scopus 로고
    • BRAF mutation status in gastrointestinal stromal tumors
    • Hostein, I. et al. BRAF mutation status in gastrointestinal stromal tumors. Am. J. Clin. Pathol. 133, 141-148 (2010
    • (2010) Am. J. Clin. Pathol , vol.133 , pp. 141-148
    • Hostein, I.1
  • 71
    • 0037225829 scopus 로고    scopus 로고
    • Imatinib mesylate: In the treatment of gastrointestinal stromal tumours
    • Croom, K. F. & Perry, C. M. Imatinib mesylate: In the treatment of gastrointestinal stromal tumours. Drugs 63, 513-522 (2003
    • (2003) Drugs , vol.63 , pp. 513-522
    • Croom, K.F.1    Perry, C.M.2
  • 72
    • 79957500033 scopus 로고    scopus 로고
    • A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST
    • Blay, J. Y. A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST. Cancer Treat. Rev. 37, 373-384 (2011
    • (2011) Cancer Treat. Rev , vol.37 , pp. 373-384
    • Blay, J.Y.1
  • 74
    • 79959795786 scopus 로고    scopus 로고
    • Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    • Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011
    • (2011) N. Engl. J. Med , vol.364 , pp. 2507-2516
    • Chapman, P.B.1
  • 75
    • 66249087984 scopus 로고    scopus 로고
    • Cancer: Melanoma troops massed
    • Huang, P. & Marais, R. Cancer: Melanoma troops massed. Nature 459, 336-337 (2009
    • (2009) Nature , vol.459 , pp. 336-337
    • Huang, P.1    Marais, R.2
  • 76
    • 84855472280 scopus 로고    scopus 로고
    • Vemurafenib and BRAF inhibition: A new class of treatment for metastatic melanoma
    • Luke, J. J. & Hodi, F. S. Vemurafenib and BRAF inhibition: A new class of treatment for metastatic melanoma. Clin. Cancer Res. 18, 9-14 (2012
    • (2012) Clin. Cancer Res , vol.18 , pp. 9-14
    • Luke, J.J.1    Hodi, F.S.2
  • 77
    • 27844567142 scopus 로고    scopus 로고
    • Distinct sets of genetic alterations in melanoma
    • Curtin, J. A. et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135-2147 (2005
    • (2005) N. Engl. J. Med , vol.353 , pp. 2135-2147
    • Curtin, J.A.1
  • 78
    • 80052782508 scopus 로고    scopus 로고
    • Molecular analysis of thyroid tumors
    • Bhaijee, F. & Nikiforov, Y. E. Molecular analysis of thyroid tumors. Endocr. Pathol. 22, 126-133 (2011
    • (2011) Endocr. Pathol , vol.22 , pp. 126-133
    • Bhaijee, F.1    Nikiforov, Y.E.2
  • 79
    • 84857076207 scopus 로고    scopus 로고
    • Quantitative cell-free DNA KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan
    • Spindler, K. L., Pallisgaard, N., Vogelius, I. & Jakobsen, A. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin. Cancer Res. 18, 1177-1185 (2012
    • (2012) Clin. Cancer Res , vol.18 , pp. 1177-1185
    • Spindler, K.L.1    Pallisgaard, N.2    Vogelius, I.3    Jakobsen, A.4
  • 80
    • 79959293462 scopus 로고    scopus 로고
    • BRAF mutations in hairy-cell leukemia
    • Tiacci, E. et al. BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 364, 2305-2315 (2011
    • (2011) N. Engl. J. Med , vol.364 , pp. 2305-2315
    • Tiacci, E.1
  • 81
    • 84863230465 scopus 로고    scopus 로고
    • Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
    • Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100-103 (2012
    • (2012) Nature , vol.483 , pp. 100-103
    • Prahallad, A.1
  • 82
    • 84861417677 scopus 로고    scopus 로고
    • BRAF inhibition in refractory hairy-cell leukemia
    • Dietrich, S. et al. BRAF inhibition in refractory hairy-cell leukemia. N. Engl. J. Med. 366, 2038-2040 (2012
    • (2012) N. Engl. J. Med , vol.366 , pp. 2038-2040
    • Dietrich, S.1
  • 83
    • 80054111050 scopus 로고    scopus 로고
    • CD30-targeted antibody therapy
    • Younes, A. CD30-targeted antibody therapy. Curr. Opin. Oncol. 23, 587-593 (2011
    • (2011) Curr. Opin. Oncol , vol.23 , pp. 587-593
    • Younes, A.1
  • 84
    • 84863678237 scopus 로고    scopus 로고
    • Brentuximab vedotin (SGN 35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study
    • Pro, B. et al. Brentuximab vedotin (SGN 35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study. J. Clin. Oncol. 30, 2190-2196 (2012
    • (2012) J. Clin. Oncol , vol.30 , pp. 2190-2196
    • Pro, B.1
  • 85
    • 79953830127 scopus 로고    scopus 로고
    • Brentuximab vedotin for the treatment of CD30+ lymphomas
    • Foyil, K. V. & Bartlett, N. L. Brentuximab vedotin for the treatment of CD30+ lymphomas. Immunotherapy 3, 475-485 (2011
    • (2011) Immunotherapy , vol.3 , pp. 475-485
    • Foyil, K.V.1    Bartlett, N.L.2
  • 87
    • 0142055937 scopus 로고    scopus 로고
    • Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial
    • Kris, M. G. et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290, 2149-2158 (2003
    • (2003) JAMA , vol.290 , pp. 2149-2158
    • Kris, M.G.1
  • 88
    • 27544503230 scopus 로고    scopus 로고
    • Gefitinib plus best supportive care in previously treated patients with refractory advanced non small cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer
    • Thatcher, N. et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non small cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366, 1527-1537 (2005
    • (2005) Lancet , vol.366 , pp. 1527-1537
    • Thatcher, N.1
  • 89
    • 20244389188 scopus 로고    scopus 로고
    • Predictive and prognostic impact of epidermal growth factor receptor mutation in non small cell lung cancer patients treated with gefitinib
    • Han, S. W. et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non small cell lung cancer patients treated with gefitinib. J. Clin. Oncol. 23, 2493-2501 (2005
    • (2005) J. Clin. Oncol , vol.23 , pp. 2493-2501
    • Han, S.W.1
  • 90
    • 2342471392 scopus 로고    scopus 로고
    • Activating mutations in the epidermal growth factor receptor underlying responsiveness of non small cell lung cancer to gefitinib
    • Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non small cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004
    • (2004) N. Engl. J. Med , vol.350 , pp. 2129-2139
    • Lynch, T.J.1
  • 91
    • 84876703546 scopus 로고    scopus 로고
    • ASCO. ASCO's Blueprint for Transforming Clinical and Translational Cancer Research
    • ASCO. ASCO's Blueprint for Transforming Clinical and Translational Cancer Research. Cancer in the Molecular Era: Identifying the Drivers of Lung Cancer [online], http://www.asco.org/ascov2/department%20content/ cancer%20policy%20and%20clinical%20affairs/downloads/blueprint.pdf (2012
    • (2012) Cancer in the Molecular Era: Identifying the Drivers of Lung Cancer [online]
  • 92
    • 84856893071 scopus 로고    scopus 로고
    • Anaplastic lymphoma kinase as a new target for the treatment of non small cell lung cancer
    • Tiseo, M. et al. Anaplastic lymphoma kinase as a new target for the treatment of non small cell lung cancer. Expert Rev. Anticancer Ther. 11, 1677-1687 (2011
    • (2011) Expert Rev. Anticancer Ther , vol.11 , pp. 1677-1687
    • Tiseo, M.1
  • 93
    • 84863943675 scopus 로고    scopus 로고
    • Crizotinib for ALK-rearranged non-small cell lung cancer: A new targeted therapy for a new target
    • Gandhi, L. & Jänne, P. A. Crizotinib for ALK-rearranged non-small cell lung cancer: A new targeted therapy for a new target. Clin. Cancer Res. 18, 3737-3742 (2012
    • (2012) Clin. Cancer Res , vol.18 , pp. 3737-3742
    • Gandhi, L.1    Jänne, P.A.2
  • 94
    • 70449378917 scopus 로고    scopus 로고
    • The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: How does it relate to the original lenalidomide experience in MDS
    • Kantarjian, H et al. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: How does it relate to the original lenalidomide experience in MDS? Cancer 115, 5202-5209 (2009
    • (2009) Cancer , vol.115 , pp. 5202-5209
    • Kantarjian, H.1
  • 95
    • 79956088970 scopus 로고    scopus 로고
    • Myelodysplastic syndromes: Update on diagnosis, risk-stratification, and management
    • Garcia-Manero, G. Myelodysplastic syndromes: Update on diagnosis, risk-stratification, and management. Am. J. Hematol. 86, 490-498 (2011
    • (2011) Am. J. Hematol , vol.86 , pp. 490-498
    • Garcia-Manero, G.1
  • 96
    • 76649129531 scopus 로고    scopus 로고
    • Lenalidomide in myelodysplastic syndromes: An erythropoiesis-stimulating agent or more
    • Komrokji, R. S., Lancet, J. E. & List, A. F. Lenalidomide in myelodysplastic syndromes: An erythropoiesis-stimulating agent or more? Curr. Hematol. Malig. Rep. 5, 9-14 (2010
    • (2010) Curr Hematol. Malig. Rep , vol.5 , pp. 9-14
    • Komrokji, R.S.1    Lancet, J.E.2    List, A.F.3
  • 97
    • 77958050048 scopus 로고    scopus 로고
    • Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes
    • Heise, C., Carter, T., Schafer, P. & Chopra, R. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes. Expert Rev. Anticancer Ther. 10, 1663-1672 (2010
    • (2010) Expert Rev. Anticancer Ther , vol.10 , pp. 1663-1672
    • Heise, C.1    Carter, T.2    Schafer, P.3    Chopra, R.4
  • 98
    • 80053621748 scopus 로고    scopus 로고
    • A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate 1 risk myelodysplastic syndromes with del5q
    • Fenaux, P. et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate 1 risk myelodysplastic syndromes with del5q. Blood 118, 3765-3776 (2011
    • (2011) Blood , vol.118 , pp. 3765-3776
    • Fenaux, P.1
  • 99
    • 33750390130 scopus 로고    scopus 로고
    • The challenges of Proteus syndrome: Diagnosis and management
    • Biesecker, L. The challenges of Proteus syndrome: Diagnosis and management. Eur. J. Hum. Genet. 14, 1151-1157 (2006
    • (2006) Eur. J. Hum. Genet , vol.14 , pp. 1151-1157
    • Biesecker, L.1
  • 100
    • 84860389181 scopus 로고    scopus 로고
    • A mosaic activating mutation in AKT1 associated with the Proteus syndrome
    • Lindhurst, M. J. et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N. Engl. J. Med. 365, 611-619 (2011
    • (2011) N. Engl. J. Med , vol.365 , pp. 611-619
    • Lindhurst, M.J.1
  • 101
    • 79955045309 scopus 로고    scopus 로고
    • Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment
    • Piha-Paul, S. A., Hong, D. S. & Kurzrock, R. Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment. J. Clin. Oncol. 29, e333-e335 (2011
    • (2011) J. Clin. Oncol , vol.29
    • Piha-Paul, S.A.1    Hong, D.S.2    Kurzrock, R.3
  • 103
    • 84655175698 scopus 로고    scopus 로고
    • Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial
    • Wells, S. A. Jr et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial. J. Clin. Oncol. 30, 134-141 (2012
    • (2012) J. Clin. Oncol , vol.30 , pp. 134-141
    • Wells Jr., S.A.1
  • 104
    • 79959936054 scopus 로고    scopus 로고
    • Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer
    • Kurzrock, R. et al. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J. Clin. Oncol. 29, 2660-2666 (2011
    • (2011) J. Clin. Oncol , vol.29 , pp. 2660-2666
    • Kurzrock, R.1
  • 105
    • 84855350870 scopus 로고    scopus 로고
    • Effectiveness of adaptive designs for phase II cancer trials
    • López, M. F., Dupuy, J. F. & Gonzalez, C. V. Effectiveness of adaptive designs for phase II cancer trials. Contemp. Clin. Trials 33, 223-227 (2012
    • (2012) Contemp. Clin. Trials , vol.33 , pp. 223-227
    • López, M.F.1    Dupuy, J.F.2    Gonzalez, C.V.3
  • 106
    • 55549126273 scopus 로고    scopus 로고
    • Anaplastic large-cell lymphoma in women with breast implants
    • de Jong, D. et al. Anaplastic large-cell lymphoma in women with breast implants. JAMA 300, 2030-2035 (2008
    • (2008) JAMA , vol.300 , pp. 2030-2035
    • De Jong, D.1
  • 109
    • 52049126174 scopus 로고    scopus 로고
    • Chemoprevention and treatment of experimental Cowden's disease By MTOR inhibition with rapamycin
    • Squarize, C. H., Castilho, R. M. & Gutkind, J. S. Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin. Cancer Res. 68, 7066-7072 (2008
    • (2008) Cancer Res , vol.68 , pp. 7066-7072
    • Squarize, C.H.1    Castilho, R.M.2    Gutkind, J.S.3
  • 110
    • 80051802494 scopus 로고    scopus 로고
    • Dermatofibrosarcoma protuberans: A clinicopathological, immunohistochemical, genetic (COL1A1-PDGFB), and therapeutic study of low-grade versus high-grade (fibrosarcomatous) tumors
    • Llombart, B. et al. Dermatofibrosarcoma protuberans: A clinicopathological, immunohistochemical, genetic (COL1A1-PDGFB), and therapeutic study of low-grade versus high-grade (fibrosarcomatous) tumors. J. Am. Acad. Dermatol. 65, 564-575 (2011
    • (2011) J. Am. Acad. Dermatol , vol.65 , pp. 564-575
    • Llombart, B.1
  • 111
    • 77957342344 scopus 로고    scopus 로고
    • Immunotoxins: A promising treatment modality for metastatic melanoma
    • Risberg, K., Fodstad, O. & Andersson, Y. Immunotoxins: A promising treatment modality for metastatic melanoma? Ochsner J. 10, 193-199 (2010
    • (2010) Ochsner J. , vol.10 , pp. 193-199
    • Risberg, K.1    Fodstad, O.2    Andersson, Y.3
  • 112
    • 33646267674 scopus 로고    scopus 로고
    • Gastrointestinal stromal tumors in a cohort of Chinese patients in Hong Kong
    • Chan, K. H. et al. Gastrointestinal stromal tumors in a cohort of Chinese patients in Hong Kong. World J. Gastroenterol. 12, 2223-2228 (2006
    • (2006) World J. Gastroenterol , vol.12 , pp. 2223-2228
    • Chan, K.H.1
  • 113
    • 60149099021 scopus 로고    scopus 로고
    • Cluster of Hodgkin's lymphoma in residents near a nonoperational petroleum refinery
    • Dahlgren, J., Klein, J. & Takhar, H. Cluster of Hodgkin's lymphoma in residents near a nonoperational petroleum refinery. Toxicol. Ind. Health 24, 683-692 (2008
    • (2008) Toxicol. Ind. Health , vol.24 , pp. 683-692
    • Dahlgren, J.1    Klein, J.2    Takhar, H.3
  • 114
    • 79954442549 scopus 로고    scopus 로고
    • Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia
    • Helbig, G. et al. Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia. Cancer Chemother. Pharmacol. 67, 967-969 (2011
    • (2011) Cancer Chemother. Pharmacol , vol.67 , pp. 967-969
    • Helbig, G.1
  • 115
    • 84868199576 scopus 로고    scopus 로고
    • Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer
    • Deshpande, H., Marler, V. & Sosa, J. A. Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer. Onco. Targets Ther. 4, 209-215 (2011
    • (2011) Onco. Targets Ther , vol.4 , pp. 209-215
    • Deshpande, H.1    Marler, V.2    Sosa, J.A.3
  • 116
    • 80054106619 scopus 로고    scopus 로고
    • Janus kinase inhibitors: An update on the progress and promise of targeted therapy in the myeloproliferative neoplasms
    • Stein, B. L., Crispino, J. D. & Moliterno, A. R. Janus kinase inhibitors: An update on the progress and promise of targeted therapy in the myeloproliferative neoplasms. Curr. Opin. Oncol. 23, 609-616 (2011
    • (2011) Curr. Opin. Oncol , vol.23 , pp. 609-616
    • Stein, B.L.1    Crispino, J.D.2    Moliterno, A.R.3
  • 117
    • 18144392678 scopus 로고    scopus 로고
    • ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma
    • Vidal, M., Wells, S., Ryan, A. & Cagan, R. ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Res. 65, 3538-3541 (2005
    • (2005) Cancer Res , vol.65 , pp. 3538-3541
    • Vidal, M.1    Wells, S.2    Ryan, A.3    Cagan, R.4
  • 118
    • 48749101265 scopus 로고    scopus 로고
    • Germline and somatic c met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients
    • Salvi, A. et al. Germline and somatic c met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients. Int. J. Oncol. 33, 271-276 (2008
    • (2008) Int. J. Oncol , vol.33 , pp. 271-276
    • Salvi, A.1
  • 119
    • 33645687784 scopus 로고    scopus 로고
    • Dasatinib (BMS 354825) inhibits KITD816V, an imatinib resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis
    • Shah, N. P. et al. Dasatinib (BMS 354825) inhibits KITD816V, an imatinib resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 108, 286-291 (2006
    • (2006) Blood , vol.108 , pp. 286-291
    • Shah, N.P.1
  • 120
    • 0030738403 scopus 로고    scopus 로고
    • All-trans retinoic acid significantly increases 5 year survival in patients with acute promyelocytic leukemia: Long-term follow-up of the New York study
    • Soignet S., Fleischauer, A., Polyak, T., Heller, G. & Warrell, R. P. Jr. All-trans retinoic acid significantly increases 5 year survival in patients with acute promyelocytic leukemia: Long-term follow-up of the New York study. Cancer Chemother. Pharmacol. 40 (Suppl.), S25-S29 (1997
    • (1997) Cancer Chemother. Pharmacol , vol.40 SUPPL.
    • Soignet, S.1    Fleischauer, A.2    Polyak, T.3    Heller, G.4    Warrell Jr., R.P.5
  • 121
    • 0000492653 scopus 로고    scopus 로고
    • All trans retinoic acid pharmacology and its impact on the treatment of acute promyelocytic leukemia
    • Adamson, P. C. All trans retinoic acid pharmacology and its impact on the treatment of acute promyelocytic leukemia. Oncologist 1, 305-314 (1996
    • (1996) Oncologist , vol.1 , pp. 305-314
    • Adamson, P.C.1
  • 122
    • 84860382327 scopus 로고    scopus 로고
    • The role of BRAF V600 mutation in melanoma
    • Ascierto, P. A. et al. The role of BRAF V600 mutation in melanoma. J. Transl. Med. 10, 85 (2012
    • (2012) J. Transl. Med , vol.10 , Issue.85
    • Ascierto, P.A.1
  • 123
    • 84866749554 scopus 로고    scopus 로고
    • Gastrointestinal stromal tumors (GIST): A rare entity, a tumor model for personalized therapy, and yet ten different molecular subtypes
    • Blay, J. Y., Le Cesne, A., Cassier, P. A. & Ray-Coquard, I. L. Gastrointestinal stromal tumors (GIST): A rare entity, a tumor model for personalized therapy, and yet ten different molecular subtypes. Discov. Med. 13, 357-367 (2012
    • (2012) Discov. Med , vol.13 , pp. 357-367
    • Blay, J.Y.1    Le Cesne, A.2    Cassier, P.A.3    Ray-Coquard, I.L.4
  • 124
    • 84863676500 scopus 로고    scopus 로고
    • Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma
    • Younes, A. et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J. Clin. Oncol. 30, 2183-2189 (2012
    • (2012) J. Clin. Oncol , vol.30 , pp. 2183-2189
    • Younes, A.1
  • 125


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.